HONG KONG, April 1, 2025 /PRNewswire/ -- On 1st April, 2025, the inaugural flight ceremony of Cambodia Airways' Phnom Penh - Hong Kong service was successfully held at Hong Kong International Airport. The event was graced by the presence of several notable guests, including Mr. Perry Yiu, MH, JP, Legislative Council Member (Tourism) of the Hong Kong Special Administrative Region, Mr. Johnny So, Honorary Treasurer & Director of the Travel Industry Council of Hong Kong, Mr. Chapman Fong, Deputy Director of Corporate Development of Airport Authority Hong Kong, Mr. Gary Zhan, Chairman of SATS HK Limited, Mr. Jesse Fang, CEO of SATS HK Limited, and other heads of relevant government departments and enterprises. Mr. Edison Duan, BOD&CEO of Cambodia Airways, led a delegation to join the guests in celebrating the inauguration of the new route.
Phnom Penh - Hong Kong is Cambodia Airways' fourth non-stop flight to the Guangdong-Hong Kong-Macau Greater Bay Area after Phnom Penh - Macau, Phnom Penh - Shenzhen and Phnom Penh - Guangzhou. Cambodia Airways' network now fully covers the four central cities of the region.
The Guangdong-Hong Kong-Macau Greater Bay Area is one of China's most economically active regions and a major export hub for China. As a world-renowned international metropolis and aviation hub, Hong Kong plays an important role in the region. Meanwhile, Cambodia is emerging as one of the fastest-growing economies in the ASEAN region and an important node of the Belt and Road Initiative. In recent years, it has become an attractive destination for Chinese investment abroad.
As the only full-service airline in Cambodia, offering high-quality business class service with unique Khmer characteristics, the airline's new Phnom Penh - Hong Kong route will not only provide more convenience for business travelers between the two places but also facilitate exchanges, deepen industrial cooperation, and promote the vitality of economic and trade development of the two places. Hong Kong tourists will also have a better travel option to Cambodia, where they can explore Khmer customs and culture and visit the country's historical sites.
In a warm display of hospitality, Cambodia Airways, together with SATS HK Limited and Megacap Aviation Service Limited, welcomed the flight crew of the KR507 Phnom Penh to Hong Kong flight with flowers to celebrate their smooth landing. Passengers boarding the return flight from Hong Kong to Phnom Penh were also presented with souvenir gifts, along with heartfelt wishes for a wonderful trip ahead. At 2pm Cambodia time, a sense of excitement filled the air as Cambodia Airways' inaugural flight KR508 from Hong Kong touched down at Phnom Penh International Airport. In a warm gesture of welcome, airport staff greeted the first group of travelers arriving on the flight with beautiful Khmer jasmine garlands. They also presented beautiful flowers to the flight crew to celebrate the success of the inaugural flight.
Cambodia Airways official website: www.cambodia-airways.com
Facebook: https://www.facebook.com/CambodiaAirways
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Cambodia Airways Successfully Launched Phnom Penh - Hong Kong Non-stop Flight
Cambodia Airways Successfully Launched Phnom Penh - Hong Kong Non-stop Flight
Cambodia Airways Successfully Launched Phnom Penh - Hong Kong Non-stop Flight
BEIJING, April 4, 2025 /PRNewswire/ -- Recently, Beijing Tsingke Biotech Co., Ltd. officially announced the appointment of Dr. Yaning Wang, a former senior expert at the FDA, as the company's Chief Scientific Advisor in the field of small nucleic acid. This collaboration injects strong momentum into Tsingke's growth in small nucleic acid drugs raw materials, marking a significant enhancement in the company's technical capabilities, regulatory compliance, and quality control.
Dr. Yaning Wang's Industry Experience and Contributions
As the global small nucleic acid drugs market rapidly expands, driven by growing demand for precise treatments targeting genetic disorders, rare diseases, and cancer. The high specificity of small nucleic acid drugs makes them particularly promising for rare diseases caused by single-gene mutations. However, this progress also comes with technical hurdles and increasingly stringent regulatory requirements. Amidst the surging market and growing regulatory challenges, Dr. Yaning Wang joins Tsingke at this pivotal moment to strengthen our capabilities on RNA technologies. His expertise will help Tsingke drive the development of high-quality, customized small nucleic acid solutions while accelerating innovation in nucleic acid drug development.
Dr. Yaning Wang has extensive experience and outstanding achievements in the pharmaceutical industry. He obtained his Bachelor's degree in Pharmacy from Peking University in 1996, followed by a Master's degree in Biochemistry from the National Anti-Doping Center in 1999. In 2003, he earned a dual degree-a Ph.D. in Pharmacy and a Master's in Statistics-from the University of Florida.
During his tenure at the U.S. Food and Drug Administration (FDA), Dr. Wang held several key positions, ultimately serving as Director of the Division of Quantitative Pharmacology in the Office of Clinical Pharmacology. He played a leading role in the approval of multiple new drugs, ensuring their safety and efficacy, and made significant contributions to the advancement of global drug regulation.
"We are thrilled to welcome Dr. Yaning Wang to Tsingke. His extensive expertise and remarkable contributions to the pharmaceutical industry will undoubtedly strengthen Tsingke position in the rapidly evolving field of small nucleic acids. Through its collaboration with Dr. Wang, Tsingke will integrate the latest global regulatory standards and compliance guidelines, strengthening regulatory management capabilities to ensure its products meet the highest quality and safety standards in complex market environments," said Shijin Ma, President of Tsingke.
About Tsingke
Tsingke leads DNA/RNA synthesis with a full-chain platform offering gene synthesis, oligo modification, antibodies, proteins, gene regulation, and detection. Backed by a 12,000㎡ R&D facility, a 100,000-class clean workshop, and 300+ IP rights, Tsingke delivers high-quality solutions trusted by 300,000+ customers worldwide.
In small nucleic acid drug development, Tsingke drives innovation in synthesis, modification, delivery, and scale-up. With an end-to-end service model-from sequence design to validation-the company supports both research and GMP-grade production through its large-scale oligo API platform. By ensuring drug safety and delivery efficiency, Tsingke provides global researchers with tailored solutions and expert support.
For more information on Tsingke, please visit https://www.tsingke.com/ or connect with us on LinkedIn at https://www.linkedin.com/company/tsingke/.
Beijing Tsingke Biotech Co., Ltd.
market@tsingke.com.cn
https://www.tsingke.com/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation
